The prevalence of B2M loss in primary tumors ranged between 0% (esophageal cancer) and 43% (breast cancer) and between 14% (renal cancer) and 56% loss (breast cancer) in metastatic disease. The gene discussed is B2M; the disease is renal carcinoma.